Delving into the Latest Updates on Canfosfamide Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Canfosfamide, Canfosfamide hydrochloride (USAN), TER 286

+ [4]

Target

DNA

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors), DNA alkylating agents

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseRespiratory Diseases+ [4]

Active Indication-

Inactive Indication

CarcinomaLocally Advanced Lung Non-Small Cell CarcinomaMetastatic breast cancer+ [6]

Originator Organization

MabVax Therapeutics, Inc.

Active Organization-

Inactive Organization

Telik, Inc.

Taiho Pharmaceutical Co., Ltd.

MabVax Therapeutics Holdings, Inc.

License Organization-

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC26H41Cl5N5O10PS

InChIKeyNECZZOFFLFZNHL-XVGZVFJZSA-N

CAS Registry439943-59-6

This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma. The study will be conducted in two stages with 5-6 patients in each indication in Stage 1 and if responses are observed an additional 10 patients in Stage 2 in each group.

Start Date01 Jun 2010

Sponsor / Collaborator

Telik, Inc.

NCT00350948

/ TerminatedPhase 3

Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5)

The purpose of this research study is to determine if Telcyta® given in combination with liposomal doxorubicin is more effective than liposomal doxorubicin alone in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer that is refractory or resistant to platinum chemotherapy.

Start Date01 May 2006

Sponsor / Collaborator

Telik, Inc.

EUCTR2006-000366-36-BE

/ CompletedPhase 3

Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory or resistant ovarian cancer

Start Date22 Mar 2006

Sponsor / Collaborator

Telik, Inc.

100 Clinical Results associated with Canfosfamide Hydrochloride

Login to view more data

100 Translational Medicine associated with Canfosfamide Hydrochloride

Login to view more data

100 Patents (Medical) associated with Canfosfamide Hydrochloride

Login to view more data

33

Literatures (Medical) associated with Canfosfamide Hydrochloride

08 Mar 2018·Journal of medicinal chemistryQ1 · MEDICINE

Glutathione S-Transferase π-Activatable O²-(Sulfonylethyl Derived) Diazeniumdiolates Potently Suppress Melanoma in Vitro and in Vivo

Q1 · MEDICINE

Article

Author: Kaur, Jatinder ; Zhang, Yinqiu ; Yuan, Haoliang ; Zou, Yu ; Wu, Jianbing ; Huang, Zhangjian ; Fei, Yue ; Zhang, Yihua ; Bhardwaj, Atul ; Knaus, Edward E.

A group of glutathione S-transferase π (GSTπ) activatable O²-(sulfonylethyl derived) diazeniumdiolates 5-12 were designed and synthesized. These compounds could be activated by GSTπ to initiate the β-elimination reaction, liberating an active vinyl sulfone-based GSH derivative and a diazeniumdiolate anion which subsequently releases NO in situ. The most active compound 6 released relatively high levels of NO and inhibited proliferation of melanoma B16 cells, superior to a diazeniumdiolate-based anticancer agent JS-K (1). Importantly, 6 had 8-fold less inhibitory activity against normal epithelial JB6 Cl 30-7b cells. The inhibitory activity of 6 could be diminished by an NO scavenger or GSTπ inhibitor. Furthermore, 6 induced nitration of mitochondrial tyrosine in B16 cells and inoculated B16 tumors in mice, which might be responsible for oxidation of protein leading to tumor suppression. Finally, 6 significantly retarded the B16 cells growth in a mouse xenograft model. These findings suggest that 6 may have a potential to treat melanoma.

01 Feb 2013·The Science of the total environmentQ2 · ENVIRONMENTAL SCIENCE & ECOLOGY

Prediction of the potential fates of future pharmaceutical compounds in indirect potable reuse systems

Q2 · ENVIRONMENTAL SCIENCE & ECOLOGY

Article

Author: Fox, Peter ; Lim, Seung Joo

The potential fates in indirect potable reuse systems of 2179 pharmaceutical compounds that currently have been used or may be introduced within the next five years were estimated using a modified quantitative structure activity relationship model. Over 90% of the pharmaceutical compounds analyzed were estimated in this study as non-persistent in indirect potable reuse systems where the final removal barrier was sub-surface transport. The removal mechanisms of biodegradation and sorption were considered in assessing their persistence. The percentage of compounds produced by biotechnology was expected to increase from less than 20% to greater than 60% in the near future and this should result in a trend of decreasing persistence for future compounds. The potential rejection in indirect potable reuse systems that use reverse osmosis (RO) as the primary barrier was statistically evaluated. In order to evaluate RO performance, a multiple linear regression analysis was done using SPSS (ver. 17) and the main rejection mechanism for low molecular weight compounds was electrostatic repulsion. Treatment by RO is capable of removing greater than 95% of future compounds and would be expected to perform as efficiently as with currently used compounds.

01 Dec 2010·Journal of hematology & oncologyQ1 · MEDICINE

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

Q1 · MEDICINE

ArticleOA

Author: Jones, Marsha R. ; Moore, Carla L. ; Brown, Gail L. ; Wolf, Judith L. ; Meng, Lisa ; Kavanagh, John J. ; Ramirez, Pedro T. ; Bast, Robert C. Jr. ; Levenback, Charles F.

Abstract:

Background:

Canfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1. This study evaluated the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum resistant ovarian cancer. Patients with platinum resistant ovarian carcinoma and measurable disease received canfosfamide at 960 mg/m2in combination with PLD at 50 mg/m2, intravenously day 1 in every 28 day cycles until tumor progression or unacceptable toxicities. The primary endpoints were objective response rate (ORR) and progression-free survival (PFS).

Results:

Canfosfamide plus PLD combination therapy was administered at 960/50 mg/m2, respectively. Thirty-nine patients received a median number of 4 cycles (range 1.0-18.0). The ORR was 27.8% (95% CI, 14.2-45.2) with a disease stabilization rate of 80.6% (95% CI, 64.0-91.8) in the evaluable population. The CA-125 marker responses correlated with the radiological findings of complete response or partial response. The median PFS was 6.0 months (95% CI, 4.2-7.9) and median survival was 17.8 months. The combination was well tolerated. Myelosuppression was managed with dose reductions and growth factor support. Grade 3 febrile neutropenia was observed in 2 patients (5.1%). Non-hematologic adverse events occurred at the expected frequency and grade for each drug alone, with no unexpected or cumulative toxicities.

Conclusions:

Canfosfamide in combination with PLD is well tolerated and active in platinum and paclitaxel refractory or resistant ovarian cancer. A randomized phase 3 study was conducted based on this supportive phase 2 study.

Trial Registration:

This study was registered at www.clinicaltrials.gov: NCT00052065.

1

News (Medical) associated with Canfosfamide Hydrochloride

02 Aug 2007

·www.biospace.com

Telik, Inc. Announces 2007 Second Quarter Financial Release, Conference Call and Webcast

PALO ALTO, Calif., Aug. 1 /PRNewswire-FirstCall/ -- Telik, Inc. announced that its 2007 second quarter conference call and webcast will be held on Wednesday, August 8, 2007 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company's financial results for the second quarter and six months ended June 30, 2007. The conference call will be accessible via Telik's website at or by telephone at 888-428-4473 or 612-332-0107. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 882545. The archive will be available from approximately 8:30 p.m. Eastern time on August 8 through August 15, 2007. Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidate is TELCYTA, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer. A second drug development candidate, TELINTRA(TM), is in clinical development for myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at . Telik, Inc. CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, Inc., +1-650-845-7728, cdeguzman@telik.com Web site:

Financial StatementSmall molecular drug

100 Deals associated with Canfosfamide Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03351	-	-	DB04972

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 3	United States	MabVax Therapeutics Holdings, Inc.	15 Oct 2007
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Telik, Inc.	30 Mar 2004
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Argentina	Telik, Inc.	30 Mar 2004
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Australia	Telik, Inc.	30 Mar 2004
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Brazil	Telik, Inc.	30 Mar 2004
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Chile	Telik, Inc.	30 Mar 2004
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Germany	Telik, Inc.	30 Mar 2004
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Italy	Telik, Inc.	30 Mar 2004
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	United Kingdom	Telik, Inc.	30 Mar 2004
metastatic non-small cell lung cancer	Phase 3	United States	Telik, Inc.	30 Mar 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00350948 (Pubmed \| Int J Gynecol Cancer)	Phase 3	Platinum-Resistant Ovarian Carcinoma	125	Canfosfamide + PLD	vmoblkrljw(piphprqzwo) = ffmftssjeo qvqujxfoht (saioqzqvqm )	Positive	01 Jul 2010
				PLD	vmoblkrljw(piphprqzwo) = svgtdglwff qvqujxfoht (saioqzqvqm )
NCT00052065 (Pubmed \| J Hematol Oncol)	Phase 2	Platinum-Resistant Epithelial Ovarian Carcinoma	-	Canfosfamide	llxtqgicbm(jbkxzcpsss) = aebbylskmk lxxvempfwh (qcyijgsorw, 14.2 - 45.2) View more	-	11 Mar 2010
ASCO2009	Phase 3	Refractory Ovarian Carcinoma \| Platinum-Resistant Ovarian Carcinoma Second line	244	Canfosfamide (C) plus pegylated liposomal doxorubicin (PLD)	dikwdiffbd(gkdewnekqk) = ztflrirhec mvshkwetkt (kckbqotlnf ) View more	-	20 May 2009
				PLD	dikwdiffbd(gkdewnekqk) = gsfnpjrudv mvshkwetkt (kckbqotlnf ) View more
Phase 3 Study (ASCO2007)	Phase 3	Platinum-Resistant Ovarian Carcinoma	247	Canfosfamide (C) plus carboplatin (P)	qwvpjgpaac(zgrgifwaqk) = fnymxafcqi fqftmeouir (zziwehzolw )	-	20 Jun 2007
				liposomal doxorubicin (D)	qwvpjgpaac(zgrgifwaqk) = uwjpnqvuqj fqftmeouir (zziwehzolw )
ASCO2007	Phase 3	-	461	Canfosfamide (C)	znuocizdgf(nklgljprdt) = mvwybzvvtk punepppfqi (gembwueznl ) View more	-	20 Jun 2007
				Pegylated liposomal doxorubicin (D)	znuocizdgf(nklgljprdt) = cfguxxgbaa punepppfqi (gembwueznl ) View more
Pubmed \| Int J Gynecol Cancer	Phase 2	Platinum-Resistant Ovarian Carcinoma	-	TLK286 (TELCYTA)	hexcxhjsht(zeusdqlziz) = toibvjwkrv yyambhermd (vgcbyjqshm ) View more	-	01 Jul 2005
ASCO2004	Phase 1/2	-	-	TLK286	rcuzawpbbx(lwnfqcdqwm) = 5 pts tocgqdfflm (cxwgghmjzs ) View more	-	15 Jul 2004
				Carboplatin
ASCO2004	Phase 1/2	Platinum-Resistant Ovarian Carcinoma	17	TLK286	baxqgfnvxp(lokocjkkxg) = gessekpayf sdlmcorsom (fqtgoaeuun ) View more	-	15 Jul 2004
				Doxil	vjwixwprcs(wsxqsbmxyu) = slnbuuljoq nsoczhacsc (ztyqypukjg )
ASCO2004	Phase 1/2	Non-Small Cell Lung Cancer	30	TLK286	szserbpzhj(qtecuuemhe) = atghvopymn fuqeymcayv (wwiuhnruww ) View more	-	15 Jul 2004
				Docetaxel	szserbpzhj(qtecuuemhe) = zhgzgzbsux fuqeymcayv (wwiuhnruww )